I agree that this site is using cookies. You can find further informations here.
X
Cartron, G.
224  results:
Search for persons X
?
1

Efficacy of anti‐PD1 therapy in relapsed or refractory NK/T..:

Marouf, A. ; Chaubard, S. ; Michot, J....
Hematological Oncology.  41 (2023)  S2 - p. 502-503 , 2023
Link: https://doi.org/10.1002/..
 
?
2

PROGNOSTIC SCORING SYSTEMS FOR SEVERE CRS AND ICANS AFTER A..:

Sesques, P. ; Di blasi, R. ; Legouill, S....
Hematological Oncology.  41 (2023)  S2 - p. 202-204 , 2023
Link: https://doi.org/10.1002/..
 
?
3

Long term follow‐up of untreated/relapsing MCL patients wit..:

Le Gouill, S. ; Morschhauser, F. ; Chiron, D....
Hematological Oncology.  41 (2023)  S2 - p. 478-479 , 2023
Link: https://doi.org/10.1002/..
 
?
4

NATHALI‐01: A PHASE 1/2A TRIAL OF UCART20X22, AN ALLOGENEIC..:

Bachy, E. ; Ramakrishnan, A. ; Thieblemont, C....
Hematological Oncology.  41 (2023)  S2 - p. 825-826 , 2023
Link: https://doi.org/10.1002/..
 
?
5

'Don't keep me waiting': estimating the impact on lifetime ..:

Maziarz, R. ; Vadgama, S. ; Pasquini, M....
Hematological Oncology.  41 (2023)  S2 - p. 541-542 , 2023
Link: https://doi.org/10.1002/..
 
?
6

COMBINING CD19‐4‐1BBL (RO7227166) WITH GLOFITAMAB IS SAFE A..:

Hutchings, M. ; Dickinson, M. ; Carlo‐Stella, C....
Hematological Oncology.  41 (2023)  S2 - p. 136-138 , 2023
Link: https://doi.org/10.1002/..
 
?
7

GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY..:

Dickinson, M. ; Carlo‐Stella, C. ; Morschhauser, F....
Hematological Oncology.  41 (2023)  S2 - p. 144-146 , 2023
Link: https://doi.org/10.1002/..
 
?
8

EE59 Real-Life Costs of Patients With Diffuse Large B-Cell ..:

Borget, I. ; Berthet, M. ; Grenier, B....
Value in Health.  26 (2023)  12 - p. S60-S61 , 2023
Link: https://doi.org/10.1016/..
 
?
9

TRANSCEND FL: PHASE 2 STUDY RESULTS OF LISOCABTAGENE MARALE..:

Morschhauser, F. ; Dahiya, S. ; Palomba, M. L....
Hematological Oncology.  41 (2023)  S2 - p. 877-880 , 2023
Link: https://doi.org/10.1002/..
 
?
10

MURANO: Final 7 year follow up and retreatment analysis in ..:

Kater, A. P. ; Harrup, R. ; Kipps, T. J....
Hematological Oncology.  41 (2023)  S2 - p. 239-242 , 2023
Link: https://doi.org/10.1002/..
 
?
11

AXICABTAGENE CILOLEUCEL AS SECOND‐LINE THERAPY FOR LARGE B‐..:

Houot, R. ; Bachy, E. ; Cartron, G....
Hematological Oncology.  41 (2023)  S2 - p. 147-148 , 2023
Link: https://doi.org/10.1002/..
 
?
12

EE223 Estimation of the T-Cell Engagers (Bi-Specific Monocl..:

Le Dissez, C. ; Le Lay, K. ; Cartron, G....
Value in Health.  26 (2023)  12 - p. S94 , 2023
Link: https://doi.org/10.1016/..
 
?
13

A low lymphocyte‐to‐monocyte ratio (LMR) predicts PFS, POD2..:

Mozas, P. ; Ammar, R. Ould ; Chartier, L....
Hematological Oncology.  41 (2023)  S2 - p. 290-291 , 2023
Link: https://doi.org/10.1002/..
 
?
14

Cell‐free DNA sequencing allows the identification of the m..:

Sako, N. ; Delfau, M. ; Bachy, E....
Hematological Oncology.  41 (2023)  S2 - p. 338-339 , 2023
Link: https://doi.org/10.1002/..
 
?
15

EARLY CTDNA CLEARANCE AFTER CAR T‐CELL INFUSION PREDICTS OU..:

Delfau‐Larue, M. ; Viailly, P. ; Cartron, G....
Hematological Oncology.  41 (2023)  S2 - p. 179-181 , 2023
Link: https://doi.org/10.1002/..
 
1-15